CI

At a glance

ClinicalIndex Comparison Record
Phase 3Unknown· 384 target
Drug / intervention
Nimotuzumab +1 moredrug
Likely dose
Nimotuzumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03837808
NCT03837808Phase 3Unknown
CompareCT.gov

A Randomized Phase III Non-inferiority Study of Radiotherapy Plus Concurrent Nimotuzumab Versus Cisplatin in Stage II-III Nasopharyngeal Carcinoma

Sun Yat-sen University·interventional·Posted Feb 12, 2019·Updated Nov 7, 2022

In Brief

A Phase 3 clinical trial evaluating Nimotuzumab and Cisplatin for Nasopharyngeal Carcinoma and 3 related conditions. Targeting 384 participants across 1 site.

Detailed Summary

This is a Phase III trial to study the effectiveness of nimotuzumab versus cisplatin combined with intensity-modulated radiation therapy (IMRT) in treating patients with stage II-III nasopharyngeal carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
CountriesChina
CollaboratorsAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University

Timeline

Phase 3UnknownOverdue
20192020202120222023202420252026
First PostedFeb 12, 2019
Enrollment StartApr 11, 2019
Primary CompletionFeb 11, 2024
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 7.4 years ago

Interventions

Nimotuzumabdrug

nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT

Cisplatindrug

cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT